<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2022.936272</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Non-structure protein ORF1ab (NSP8) in SARS-CoV-2 contains potential &#x03B3;&#x03B4;T cell epitopes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Du</surname> <given-names>Boyu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1862491/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Guo</surname> <given-names>Yang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname> <given-names>Gang</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhu</surname> <given-names>Yunhe</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname> <given-names>Yunfu</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/452770/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Xi</surname> <given-names>Xueyan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/875791/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Institute of Basic Medical Science, Hubei University of Medicine</institution>, <addr-line>Shiyan</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine</institution>, <addr-line>Shiyan</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Renmin Hospital, Hubei University of Medicine</institution>, <addr-line>Shiyan</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Institute of Neuroscience, Hubei University of Medicine</institution>, <addr-line>Shiyan</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Bin Su, Capital Medical University, China</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Lauro Velazquez-Salinas, Plum Island Animal Disease Center, Agricultural Research Service (USDA), United States; Shetty Ravi Dyavar, Adicet Bio, Inc., United States</p></fn>
<corresp id="c001">&#x002A;Correspondence: Yunfu Wang, <email>wyfymc@sina.com</email></corresp>
<corresp id="c002">Xueyan Xi, <email>xixueyan2001@126.com</email></corresp>
<fn fn-type="equal" id="fn002"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
<fn fn-type="other" id="fn004"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>07</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>936272</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>05</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>06</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2022 Du, Guo, Li, Zhu, Wang and Xi.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Du, Guo, Li, Zhu, Wang and Xi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Upon activation by the pathogen through T-cell receptors (TCRs), &#x03B3;&#x03B4;T cells suppress the pathogenic replication and thus play important roles against viral infections. Targeting SARS-CoV-2 <italic>via</italic> &#x03B3;&#x03B4;T cells provides alternative therapeutic strategies. However, little is known about the recognition of SARS-CoV-2 antigens by &#x03B3;&#x03B4;T cells. We discovered a specific V&#x03B3;9/&#x03B4;2 CDR3 by analyzing &#x03B3;&#x03B4;T cells derived from the patients infected by SARS-CoV-2. Using a cell model exogenously expressing &#x03B3;&#x03B4;-TCR established, we further screened the structural motifs within the CDR3 responsible for binding to &#x03B3;&#x03B4;-TCR. Importantly, these sequences were mapped to NSP8, a non-structural protein in SARS-CoV-2. Our results suggest that NSP8 mediates the recognition by &#x03B3;&#x03B4;T cells and thus could serve as a potential target for vaccines.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>&#x03B3;&#x03B4;T cells</kwd>
<kwd>CDR3</kwd>
<kwd>ORF1ab</kwd>
<kwd>NSP8</kwd>
</kwd-group>
<contract-sponsor id="cn001">Natural Science Foundation of Hubei Province<named-content content-type="fundref-id">10.13039/501100003819</named-content></contract-sponsor>
<contract-sponsor id="cn002">Health Commission of Hubei Province<named-content content-type="fundref-id">10.13039/100017958</named-content></contract-sponsor>
<counts>
<fig-count count="3"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="37"/>
<page-count count="8"/>
<word-count count="4830"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p>Coronavirus disease 2019 (COVID-19) has been swept across the globe due to its extreme fast transmission speed and high pathogenic potential (<xref ref-type="bibr" rid="B14">Jin et al., 2020</xref>; <xref ref-type="bibr" rid="B34">Yang et al., 2020</xref>). By June 2022, there have been 529,410,287 confirmed cases of COVID-19, resulting in 6,296,771 deaths.<sup><xref ref-type="fn" rid="footnote1">1</xref></sup> Vaccination so far has been the key to the success in controlling the pandemic. With the danger of new variants looming around, more efforts are dedicated to developing alternative approaches for immunization.</p>
<p>&#x03B3;&#x03B4;T cells are increasingly recognized for important roles against viral infection (<xref ref-type="bibr" rid="B24">Rojas et al., 2002</xref>; <xref ref-type="bibr" rid="B7">Cao and He, 2005</xref>; <xref ref-type="bibr" rid="B12">Holtmeier and Kabelitz, 2005</xref>; <xref ref-type="bibr" rid="B37">Zhang et al., 2006</xref>). Primarily distributed within mucosa and subcutaneous tissues in skin, small intestine, lung, and reproductive organs, &#x03B3;&#x03B4;T cells account for 0.5&#x2013;5% of peripheral blood mononuclear cells. V&#x03B3;9&#x03B4;2T cells give rise to the main subtype of peripheral &#x03B3;&#x03B4;T cells. Virus-activated &#x03B3;&#x03B4;T cells could trigger a series of antiviral responses including release of cytokines (including IFN-&#x03B3;, TNF-&#x03B1;, and IL-17), restriction of viral replication, and cytolysis of virus-infected cells (<xref ref-type="bibr" rid="B15">Jouan et al., 2020</xref>; <xref ref-type="bibr" rid="B17">Lei et al., 2020</xref>; <xref ref-type="bibr" rid="B35">Yazdanifar et al., 2020</xref>; <xref ref-type="bibr" rid="B22">Orumaa and Dunne, 2022</xref>). Multiple mechanisms have been proposed for the recognition of SARS-CoV-2 by &#x03B3;&#x03B4;T cells. TLRs (Toll-like receptors), a member of pattern recognition receptors, recognize SARS-CoV-2 RNA and mediate the activation of &#x03B3;&#x03B4;T cells (<xref ref-type="bibr" rid="B11">Hirsh and Junger, 2008</xref>). NKG2D receptors bind with MIAC/B and ULBP molecules that are expressed on the surface of SARS-CoV-2 infected cells (<xref ref-type="bibr" rid="B9">Ghadially et al., 2017</xref>). In addition, TCR receptor can bind with phosphorylated antigen and protein antigen (<xref ref-type="bibr" rid="B27">Spencer et al., 2008</xref>). In spite of phosphoantigen being regarded as the main &#x03B3;&#x03B4; TCR-recognized antigen, phosphoantigen-activated &#x03B3;&#x03B4;T cells display restricted TCR diversity, and only a subset of phosphoantigen-responsive &#x03B3;&#x03B4;T cells mediate protective immunity against microorganisms (<xref ref-type="bibr" rid="B24">Rojas et al., 2002</xref>; <xref ref-type="bibr" rid="B27">Spencer et al., 2008</xref>; <xref ref-type="bibr" rid="B19">Morath and Schamel, 2020</xref>). Previously, we have observed that protein antigens could be recognized by &#x03B3;&#x03B4;T cells, and activated &#x03B3;&#x03B4;T cells could effectively induce innate and adaptive immunity against microorganisms (<xref ref-type="bibr" rid="B6">Boom et al., 1994</xref>; <xref ref-type="bibr" rid="B33">Xi et al., 2013</xref>, <xref ref-type="bibr" rid="B30">2021</xref>). However, the entity of antigenic components in SARS-CoV-2 recognized by TCR remains obscure.</p>
<p>With a strategy for screening &#x03B3;&#x03B4;TCR-specific antigen epitopes established previously (<xref ref-type="bibr" rid="B31">Xi et al., 2011a</xref>,<xref ref-type="bibr" rid="B32">b</xref>, <xref ref-type="bibr" rid="B33">2013</xref>), we revealed NSP8, a non-structural protein of SARS-CoV-2, as a strong candidate target for &#x03B3;&#x03B4;T cells mediated by &#x03B3;&#x03B4;TCR, thus opening up more space for the development of alternative vaccination schemes.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<sec id="S2.SS1">
<title>Subjects</title>
<p>Twenty COVID-19 patients were recruited at Xiyuan and Renmin Hospitals in Shiyan City, Hubei province, China. Ten healthy donors were recruited at Renmin Hospital in Shiyan City. The protocol for this study has received approval from the Clinical Ethics Committee of Hubei University of Medicine (No. 2020-TH-017). COVID-19 patients and healthy donors were all free from tumors, other infections, and diseases. All individuals had given their informed consent to participate in this study. The median ages of COVID-19 patients and healthy subjects were 42.8 and 39.3, respectively. The sex ratio for males and females is 12/8 in COVID-19 patients and 6/4 in healthy donors.</p>
</sec>
<sec id="S2.SS2">
<title>RNA extraction and reverse transcription polymerase chain reaction</title>
<p>Total RNA was extracted separately from the peripheral blood of COVID-19 patients and healthy donors. One microgram of total RNA was then converted into cDNA using a reverse transcription system. Primer sequences complementary to upstream V regions and downstream C regions were used to amplify the CDR3 regions. The primer sequences were listed in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap position="float" id="T1">
<label>TABLE 1</label>
<caption><p>The primer sequences.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left">Primer name</td>
<td valign="top" align="left">Primer sequence</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">&#x03B3;9CDR3-up</td>
<td valign="top" align="left">5&#x2032;-AATGTAGAGAAACAGGAC-3&#x2032;</td>
</tr>
<tr>
<td valign="top" align="left">&#x03B3;9CDR3-down</td>
<td valign="top" align="left">5&#x2032;-ATCTGTAATGATAAGCTTT-3&#x2032;</td>
</tr>
<tr>
<td valign="top" align="left">&#x03B4;2CDR3-up</td>
<td valign="top" align="left">5&#x2032;-GCACCATCAGAGAGAGATGAAGGG-3&#x2032;</td>
</tr>
<tr>
<td valign="top" align="left">&#x03B4;2CDR3-down</td>
<td valign="top" align="left">5&#x2032;-AAACGGATGGTTTGGTATGAGGC-3&#x2032;</td>
</tr>
<tr>
<td valign="top" align="left">Sequencing primer 1</td>
<td valign="top" align="left">5&#x2032;- TTATTCGCAATTCCTTTAGTG -3&#x2032;</td>
</tr>
<tr>
<td valign="top" align="left">Sequencing primer 2</td>
<td valign="top" align="left">5&#x2032;- GCCCTCATAGTTAGCGTAACG -3&#x2032;</td>
</tr>
</tbody>
</table></table-wrap>
</sec>
<sec id="S2.SS3">
<title>Cloning and sequencing of V&#x03B3;9 and V&#x03B4;2 CDR3 regions</title>
<p>The purified PCR products were ligated into pGEM-T easy vector (Invitrogen, Carlsbad, CA, United States) and sequenced by using T7 primer (Sangon Biotech Inc., Shanghai, China). The CDR3&#x03B3; region was considered to contain conserved &#x201C;CALW&#x201D; at its N-terminus and conserved &#x201C;KVFG&#x201D; at its C-terminus. While CDR3&#x03B4; region was considered to contain conserved &#x201C;CA&#x201D; at its N-terminus and conserved &#x201C;FGXG&#x201D; at its C-terminus.</p>
</sec>
<sec id="S2.SS4">
<title>Construction of SARS-CoV-2-specific &#x03B3;&#x03B4;TCR transfected cells</title>
<p>The SARS-CoV-2 specific CDR3 sequences were separately inserted into full-length &#x03B3;9 and &#x03B4;2 chains to substitute their original CDR3 sequences based on our previous report (<xref ref-type="bibr" rid="B32">Xi et al., 2011b</xref>). The obtained &#x03B3;9 and &#x03B4;2 chains were then inserted into pREP7 and pREP9 vectors (<xref ref-type="fig" rid="F1">Figure 1A</xref>), respectively. Full-length pREP7-&#x03B3;9 and pREP9-&#x03B4;2 chains were co-transfected into J.RT3-T3.5 cells. After 48 h, the transfected cells were cultured in a selection medium with hygromycin and neomycin for 4 weeks. The expression of transfected &#x03B3;&#x03B4;TCR in the cells was then evaluated by flow cytometry.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Construction of SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells. <bold>(A)</bold> The map of pREP7 and pREP9 vectors. <bold>(B)</bold> Detection of &#x03B3;&#x03B4;TCR expression by PCR in transfected J.RT3-T3.5 cells. mRNA was extracted from transfected cells and reverse transcribed into cDNA. The full-length &#x03B3;9 and &#x03B4;2 chains and their CDR3 sequences were amplified by using specific PCR primers. <bold>(C)</bold> Detection of &#x03B3;&#x03B4;TCR expression by FACS analysis in J.RT3-T3.5 transfected cells. The cells were stained with FITC-labeled &#x03B3;&#x03B4;TCR antibody and then analyzed by flow cytometry on a MoFlo XDP flow cytometer. The results are representative of three independent experiments. SARS-CoV-2 cells: SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected J.RT-T3.5 cells; Control cells: healthy controls&#x2019; &#x03B3;&#x03B4;TCR transfected J.RT-T3.5 cells. J.RT-T3.5 cells: J.RT-T3.5 cells without plasmid transfection.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-936272-g001.tif"/>
</fig>
</sec>
<sec id="S2.SS5">
<title><italic>In vitro</italic> panning</title>
<p>The transfected cells expressing potential SARS-CoV-2 specific &#x03B3;&#x03B4;TCR were used as probe cells to perform subtractive screening in a 12-peptide phage-display library. Four rounds of screening with conditions such as increased Tween concentration, increased action time with control cells as well as decreased action time with SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells were conducted in order to enrich epitope peptides that could specifically bind with SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells.</p>
</sec>
<sec id="S2.SS6">
<title>Peptide synthesis</title>
<p>Sangon Biotech Inc. synthesized peptides with a purity of more than 95% as determined by high-performance liquid chromatography analysis. Half of the synthesized peptides were linked with FITC at their N-terminals.</p>
</sec>
<sec id="S2.SS7">
<title>Flow cytometry</title>
<p>Cells were incubated with FITC-conjugated peptide or control peptide for 30 min at 4&#x00B0;C. The cells were then analyzed by flow cytometry on a MoFlo XDP flow cytometer (Beckman Coulter, Fullerton, CA, United States).</p>
</sec>
<sec id="S2.SS8">
<title>Magnetic-activated cell sorting</title>
<p>&#x03B3;&#x03B4;T cells were isolated from healthy donors&#x2019; peripheral blood mononuclear cells (PBMCs) using an anti-TCR &#x03B3;/&#x03B4; MicroBead Kit from Miltenyi company (130-050-701) according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="S2.SS9">
<title>Protein-immobilized amplification assay</title>
<p>The transfected cells and sorted &#x03B3;&#x03B4;T cells were separately incubated with 10 ng/mL NSP8 protein (Sino Biological Inc., Beijing, China) or control protein for 30 min at room temperature. After extensive washing with RPMI-1640 culture medium, the transfected cells and natural &#x03B3;&#x03B4;T cells were then plated into 24-well plates at 1 &#x00D7; 10<sup>6</sup> cells per well. The supernatants were harvested after 24 h and the level of IL-2 was detected by using Human IL-2 ELISA Kit (BD Biosciences, San Jose, CA, United States) according to the manufacture&#x2019;s instructions.</p>
</sec>
<sec id="S2.SS10">
<title>Bioinformatics analysis</title>
<p>The homologous analysis and sequence alignment were performed by using the Basic Local Alignment Search Tool (BLAST) to identify the matched proteins. After the screening, the obtained epitope peptide candidates were analyzed on the Heliquest website.<sup><xref ref-type="fn" rid="footnote2">2</xref></sup> The sequence alignment between peptide candidates and the downloaded SARS-CoV-2 ORF1ab sequence was performed by using DNAMAN8 software.</p>
</sec>
<sec id="S2.SS11">
<title>Statistical analysis</title>
<p>Statistical comparisons between the experiment group and control group were performed by using the Student&#x2019;s <italic>t</italic>-test. All data were analyzed either by SPSS 19.0 software or by GraphPad 8.0 software. <italic>P</italic> &#x003C; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="S3" sec-type="results">
<title>Results</title>
<sec id="S3.SS1">
<title>A specific CDR3&#x03B4;2 sequence derived from COVID-19 patients</title>
<p>The specificity in antigen recognition by TCR is primarily determined by the sequences within CDR3 region that are highly diverse. We isolated peripheral &#x03B3;&#x03B4;T cells from the patients infected by SARS-CoV-2 viruses and analyzed both V&#x03B3;9 CDR3 and V&#x03B4;2 TCR regions in comparison to the sequences derived from healthy donors. There was no significant variation in V&#x03B3;9 CDR3 region identified between the infected and control groups (<xref ref-type="table" rid="T2">Table 2</xref>). However, in V&#x03B4;2 region, we found a CDR3 sequence specifically present in most of the infected cases (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap position="float" id="T2">
<label>TABLE 2</label>
<caption><p>Deduced V&#x03B3;9 CDR3 amino acid sequences of COVID-19 patients and healthy donors<xref ref-type="table-fn" rid="t2fna"><sup>a</sup></xref>.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="center">Clone</td>
<td valign="top" align="center">V region</td>
<td valign="top" align="center">N/P region</td>
<td valign="top" align="center">J region</td>
<td valign="top" align="center">Frequency<xref ref-type="table-fn" rid="t2fnb"><sup>b</sup></xref></td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">COVID-19 patients</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">APQ</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">8/60</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">2</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">VIS</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">8/60</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">3</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">PPV</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">3/60</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">4</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">VACY</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">2/60</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">5</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">GIC</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">2/60</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">6</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">KKA</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">2/60</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">7</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">DEHK</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">2/60</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">8</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">PYQ</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">2/60</td>
</tr>
<tr>
<td valign="top" align="left">Healthy donors</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center"><italic>CALWE</italic></td>
<td valign="top" align="center"><italic>VIS</italic></td>
<td valign="top" align="center"><italic>ELGKKIKVFG</italic></td>
<td valign="top" align="center"><italic>4/30</italic></td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">2</td>
<td valign="top" align="center"><italic>CALWE</italic></td>
<td valign="top" align="center"><italic>APG</italic></td>
<td valign="top" align="center"><italic>ELGKKIKVFG</italic></td>
<td valign="top" align="center"><italic>4/30</italic></td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">3</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">SKR</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">2/30</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">4</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">GETP</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">1/30</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">5</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">PLAAA</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">1/30</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">6</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">GNSY</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">1/30</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">7</td>
<td valign="top" align="center">CALW</td>
<td valign="top" align="center">RRSG</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">1/30</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">8</td>
<td valign="top" align="center">CALWE</td>
<td valign="top" align="center">QIIEF</td>
<td valign="top" align="center">ELGKKIKVFG</td>
<td valign="top" align="center">1/30</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t2fna"><p><sup>a</sup>Total RNA was extracted separately from the peripheral blood of COVID-19 patients and healthy donors. One microgram of total RNA was then converted into cDNA using a reverse transcription system. Primer sequences complementary to upstream V regions and downstream C regions were used to amplify the CDR3 regions. The purified PCR products were ligated into pGEM-T easy vector and sequenced. The CDR3&#x03B3; region was considered to contain conserved &#x201C;CALW&#x201D; at its N-terminus and conserved &#x201C;KVFG&#x201D; at its C-terminus.</p></fn>
<fn id="t2fnb"><p><sup>b</sup>Number of identical clones/total number of clones sequenced. Not all the sequencing results were listed in the table.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap position="float" id="T3">
<label>TABLE 3</label>
<caption><p>Deduced V&#x03B4;2 CDR3 amino acid sequences of COVID-19 patients and healthy donors<xref ref-type="table-fn" rid="t3fna"><sup>a</sup></xref>.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="center">Clone</td>
<td valign="top" align="center">V region</td>
<td valign="top" align="center">N-D-N region</td>
<td valign="top" align="center">J region</td>
<td valign="top" align="center">Frequency<xref ref-type="table-fn" rid="t3fnb"><sup>b</sup></xref></td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">COVID-19 patients</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">PLLGDASY</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">18/80</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">2</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">VLGA</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">6/80</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">3</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">RLSP</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">6/80</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">4</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">TLVS</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">4/80</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">5</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">VRLS</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">3/80</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">6</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">SLLGDSEY</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">3/80</td>
</tr>
<tr>
<td valign="top" align="left">Healthy donors</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">RLGDTG</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">5/40</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">2</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center"><italic>TLVS</italic></td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">4/40</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">3</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">PLEAP</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">3/40</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">4</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">PLTS</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">2/40</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">5</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">ALLI</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">2/40</td>
</tr>
<tr>
<td valign="top" align="center"/><td valign="top" align="center">6</td>
<td valign="top" align="center">CACD</td>
<td valign="top" align="center">VLPG</td>
<td valign="top" align="center">TDKLIFGKG</td>
<td valign="top" align="center">2/40</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t3fna"><p><sup>a</sup>Total RNA was extracted separately from the peripheral blood of COVID-19 patients and healthy donors. One microgram of total RNA was then converted into cDNA using a reverse transcription system. Primer sequences complementary to upstream V regions and downstream C regions were used to amplify the CDR3 regions. The purified PCR products were ligated into pGEM-T easy vector and sequenced. The CDR3&#x03B4; region was considered to contain conserved &#x201C;CA&#x201D; at its N-terminus and conserved &#x201C;FGXG&#x201D; at its C-terminus.</p></fn>
<fn id="t3fnb"><p><sup>b</sup>Number of identical clones/total number of clones sequenced. Not all the sequencing results were listed in the table.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S3.SS2">
<title>The identification of SARS-CoV-2-specific &#x03B3;&#x03B4;TCRs binding epitopes</title>
<p>We amplified the sequences encoding &#x03B3;&#x03B4;TCRs derived from either infected patients or healthy individuals. The &#x03B3;9 sequence (CALWEVISELGKKIKVFG) was identical between the two groups, whereas the &#x03B4;2 sequences were different, with CACDPLLGDASYTDKLIFGKG from COVID-19 patients and CACDRLGDTGTDKLIFGKG from healthy individuals. We then established the expressions of full length &#x03B3;9 and &#x03B4;2 chains <italic>via</italic> introducing the designated vectors into J.RT3-T3.5 cells by electroporation (see more details in section &#x201C;Materials and Methods&#x201D;). After 4 weeks of selection with hygromycin and neomycin, the SARS-CoV-2-specific &#x03B3;&#x03B4;TCRs lines established were verified by both PCR (<xref ref-type="fig" rid="F1">Figure 1B</xref>) and flow cytometry (<xref ref-type="fig" rid="F1">Figure 1C</xref>).</p>
<p>Next, we used this cell model to screen potential epitopes recognized by this &#x03B3;&#x03B4;TCR based on a 12-mer random peptide phage-display library (E8110S, New England Biolabs, Hitchin, United Kingdom) (<xref ref-type="bibr" rid="B32">Xi et al., 2011b</xref>). There were 20 positive clones obtained as indicated by the phage-ELISA. Sequences derived from these clones were sequenced and gave rise to the dominant epitope candidates (SP1 to SP8) (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<table-wrap position="float" id="T4">
<label>TABLE 4</label>
<caption><p>The sequence of epitope peptide candidates<xref ref-type="table-fn" rid="t4fna"><sup>a</sup></xref>.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left">Name</td>
<td valign="top" align="left">Sequence</td>
<td valign="top" align="center">Frequency<xref ref-type="table-fn" rid="t4fnb"><sup>b</sup></xref></td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">SP1</td>
<td valign="top" align="left">KKLKKSLTLPLQ</td>
<td valign="top" align="center">6/20</td>
</tr>
<tr>
<td valign="top" align="left">SP2</td>
<td valign="top" align="left">YTPQLPSYAAFA</td>
<td valign="top" align="center">5/20</td>
</tr>
<tr>
<td valign="top" align="left">SP3</td>
<td valign="top" align="left">VSRHALWELQQS</td>
<td valign="top" align="center">4/20</td>
</tr>
<tr>
<td valign="top" align="left">SP4</td>
<td valign="top" align="left">SLNVAKSESCLH</td>
<td valign="top" align="center">1/20</td>
</tr>
<tr>
<td valign="top" align="left">SP5</td>
<td valign="top" align="left">YKVVIFDWRRSD</td>
<td valign="top" align="center">1/20</td>
</tr>
<tr>
<td valign="top" align="left">SP6</td>
<td valign="top" align="left">KDAHPESEFDRD</td>
<td valign="top" align="center">1/20</td>
</tr>
<tr>
<td valign="top" align="left">SP7</td>
<td valign="top" align="left">KHKHPPFDPSRP</td>
<td valign="top" align="center">1/20</td>
</tr>
<tr>
<td valign="top" align="left">SP8</td>
<td valign="top" align="left">AQTPVSYSPTTF</td>
<td valign="top" align="center">1/20</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t4fna"><p><sup>a</sup>According to the results of phage-ELISA, 20 phage clones that could specifically bind with SARS-CoV-2-specific &#x03B3;&#x03B4;TCR transfected cells were obtained and amplified by RT-PCR. The PCR products were then sequenced and the corresponding amino acid sequences were analyzed. Eight dominant epitope candidates (SP1 to SP8) were obtained.</p></fn>
<fn id="t4fnb"><p><sup>b</sup>Number of identical clones/total number of clones sequenced.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S3.SS3">
<title>Identified dominant epitopes bind to SARS-CoV-2-specific &#x03B3;&#x03B4;TCR</title>
<p>We used the SARS-CoV-2-specific &#x03B3;&#x03B4;TCR cell model to verify the binding between the epitopes identified and &#x03B3;&#x03B4;TCR. IL-2 secretion was monitored by ELISA in the cells upon the stimulation with individual epitope peptides. Among three representative epitopes SP1, SP2, and SP3 highlighted in <xref ref-type="fig" rid="F2">Figure 2A</xref> (The predicted spiral structures were obtained using bioinformatics analysis tools proved by Heliquest website.), SP1 and SP2 triggered significant IL-2 production in the cells (<xref ref-type="fig" rid="F2">Figure 2B</xref>) (<italic>P</italic> &#x003C; 0.05). FACS analysis using FITC-conjugated peptides also confirmed that SP1 and SP2 exhibited strong affinity toward the SARS-CoV-2-specific &#x03B3;&#x03B4;TCR cells (<xref ref-type="fig" rid="F2">Figure 2C</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Confirmation of peptide binding to SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells. <bold>(A)</bold> Spiral structure of three identified peptides predicted by bioinformatics tools on the Heliquest website (<ext-link ext-link-type="uri" xlink:href="http://heliquest.ipmc.cnrs.fr/?tdsourcetag=s_pcqq_aiomsg">http://heliquest.ipmc.cnrs.fr/?tdsourcetag=s_pcqq_aiomsg</ext-link>). <bold>(B)</bold> IL-2 secretion after stimulation by the identified peptides in SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells. The three peptides and control peptide were separately co-cultured with SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells and control cells for 24 h. IL-2 production in the supernatant of the cell culture medium was detected by ELISA. Data was presented as mean &#x00B1; SD from triplicate experiments. <bold>(C)</bold> The results of FACS analysis revealed the affinity between identified peptides and SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells. The identified peptides and control peptides had been conjugated with FITC (10 &#x03BC;g) and were separately co-cultured with SARS-CoV-2-specific &#x03B3;&#x03B4;TCR transfected cells. The results showed that SP1 (76.3%) and SP2 (58.9%) could bind more effectively to the transfected cells than SP3 (2.78%). The results are representative of three independent experiments. <sup>&#x2217;</sup>Denotes <italic>p</italic> &#x003C; 0.05.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-936272-g002.tif"/>
</fig>
</sec>
<sec id="S3.SS4">
<title>NSP8 protein in SARS-CoV-2 ORF1ab region contains potential epitopes that could activate &#x03B3;&#x03B4;T cells</title>
<p>A BLAST search was performed to identify SARS-CoV-2 proteins that contain SP1 and SP2 epitopes (<xref ref-type="table" rid="T5">Table 5</xref>). The top hits were located in ORF1ab region that encodes non-structural polyproteins involved in virus assembly, transcription, and replication. Further analysis using DNAMAN8 software revealed NSP8, among the ORF1ab region-derived polypeptides, as the origin of these &#x03B3;&#x03B4;TCR-specific epitopes (<xref ref-type="fig" rid="F3">Figure 3A</xref>). NSP8 stimulates the production of IL-2 in the SARS-CoV-2-specific &#x03B3;&#x03B4;TCR cells, which were evident at both transcriptional (Real-time PCR, <xref ref-type="fig" rid="F3">Figure 3B</xref>) and translational (ELISA, <xref ref-type="fig" rid="F3">Figure 3C</xref>) levels. Furthermore, INF-&#x03B3; production has been linked to &#x03B3;&#x03B4;T cell activation (<xref ref-type="bibr" rid="B32">Xi et al., 2011b</xref>,<xref ref-type="bibr" rid="B33">2013</xref>, <xref ref-type="bibr" rid="B30">2021</xref>). Our findings also demonstrated that NSP8 could activate peripheral &#x03B3;&#x03B4;T cells isolated from healthy donors and increase INF-&#x03B3; secretion in these cells, implying that NSP8 could bind to natural &#x03B3;&#x03B4;T cells (<xref ref-type="fig" rid="F3">Figure 3D</xref>).</p>
<table-wrap position="float" id="T5">
<label>TABLE 5</label>
<caption><p>BLAST analysis of epitope peptide candidates.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="left">Reference no.</td>
<td valign="top" align="left">Protein name</td>
<td valign="top" align="left">Species</td>
<td valign="top" align="center">E value</td>
<td valign="top" align="left">Matching part</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">SP1</td>
<td valign="top" align="left">UEX01438.1</td>
<td valign="top" align="left">ORF1a polyprotein</td>
<td valign="top" align="left">SARS-CoV-2</td>
<td valign="top" align="center">26.5</td>
<td valign="top" align="left">KKLKKSLT</td>
</tr>
<tr>
<td valign="top" align="left">SP1</td>
<td valign="top" align="left">UEX01439.1</td>
<td valign="top" align="left">ORF1ab polyprotein</td>
<td valign="top" align="left">SARS-CoV-2</td>
<td valign="top" align="center">26.5</td>
<td valign="top" align="left">KKLKKSLT</td>
</tr>
<tr>
<td valign="top" align="left">SP1</td>
<td valign="top" align="left">UMA92726.1</td>
<td valign="top" align="left">ORF1ab polyprotein</td>
<td valign="top" align="left">SARS-CoV-2</td>
<td valign="top" align="center">25.7</td>
<td valign="top" align="left">KKLKKSL L</td>
</tr>
<tr>
<td valign="top" align="left">SP2</td>
<td valign="top" align="left">UGC79169.1</td>
<td valign="top" align="left">ORF1ab polyprotein</td>
<td valign="top" align="left">SARS-CoV-2</td>
<td valign="top" align="center">27.8</td>
<td valign="top" align="left">LPSYAAFA</td>
</tr>
<tr>
<td valign="top" align="left">SP2</td>
<td valign="top" align="left">UJY79755.1</td>
<td valign="top" align="left">ORF1ab polyprotein</td>
<td valign="top" align="left">SARS-CoV-2</td>
<td valign="top" align="center">27.8</td>
<td valign="top" align="left">LPSYAAFA</td>
</tr>
<tr>
<td valign="top" align="left">SP2</td>
<td valign="top" align="left">UJE21816.1</td>
<td valign="top" align="left">ORF1ab polyprotein</td>
<td valign="top" align="left">SARS-CoV-2</td>
<td valign="top" align="center">27.8</td>
<td valign="top" align="left">LPSYAAFA</td>
</tr>
</tbody>
</table></table-wrap>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>NSP8 protein contains potential epitopes that could activate &#x03B3;&#x03B4;T cell. <bold>(A)</bold> The sequence alignment of two peptide candidates with the sequence of SARS-CoV-2 and NSP8 protein sequence. <bold>(B,C)</bold> NSP8 protein could stimulate SARS-CoV-2 specific &#x03B3;&#x03B4;TCR transfected cells to produce more IL-2. The control protein and NSP8 protein were pre-coated in a 24-well plate. The SARS-CoV-2-specific &#x03B3;&#x03B4;TCR transfected cells were then added and cultured for 24 h. IL-2 secretion was measured either by RT-PCR (B) or by ELISA <bold>(C)</bold>. <bold>(D)</bold> NSP8 protein could bind to natural peripheral &#x03B3;&#x03B4;T cells. The control protein and NSP8 protein were pre-coated in a 24-well plate and incubated with &#x03B3;&#x03B4;T cells isolated from five healthy donors&#x2019; peripheral blood. IFN-&#x03B3; secretion was measured in supernatants collected 24 h after incubation. Data were presented as mean &#x00B1; SD from triplicate experiments. <sup>&#x2217;</sup>Denotes <italic>p</italic> &#x003C; 0.05; <sup>&#x2217;&#x2217;</sup>Denotes <italic>p</italic> &#x003C; 0.01.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmicb-13-936272-g003.tif"/>
</fig>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>Similar to &#x03B1;&#x03B2;T cells, &#x03B3;&#x03B4;T cells secrete granzyme and perforin that target infected cells. This action normally is in conjunction with the expressions of FasL and TNF related apoptosis inducing ligand (TRAIL) that render targeted cells for apoptosis. In parallel, &#x03B3;&#x03B4;T cells orchestrate other immune cells to participate in antiviral responses, which is mainly mediated by cytokines and membrane molecules derived from &#x03B3;&#x03B4;T cells (<xref ref-type="bibr" rid="B12">Holtmeier and Kabelitz, 2005</xref>; <xref ref-type="bibr" rid="B37">Zhang et al., 2006</xref>; <xref ref-type="bibr" rid="B8">Carissimo et al., 2020</xref>; <xref ref-type="bibr" rid="B18">Lo Presti et al., 2021</xref>). However, unlike the case of &#x03B1;&#x03B2;T subtype, the recognition of antigens by &#x03B3;&#x03B4;T cells does not require antigen presentation from antigen-presenting cells (APC) (<xref ref-type="bibr" rid="B7">Cao and He, 2005</xref>; <xref ref-type="bibr" rid="B29">Xi et al., 2009</xref>, <xref ref-type="bibr" rid="B28">2010</xref>), thus making this population of T cells attractive for alternative anti-infectious therapeutic development (<xref ref-type="bibr" rid="B20">Odak et al., 2020</xref>; <xref ref-type="bibr" rid="B23">Rijkers et al., 2020</xref>). We previously established a &#x03B3;&#x03B4;TCR <italic>ex vivo</italic> expression cell model for identifying antigens recognizable by &#x03B3;&#x03B4;T cells (<xref ref-type="bibr" rid="B31">Xi et al., 2011a</xref>,<xref ref-type="bibr" rid="B32">b</xref>, <xref ref-type="bibr" rid="B33">2013</xref>). Here we took this approach to identify potential antigens of SARS-CoV-2 specific for &#x03B3;&#x03B4;T cells. SP1 and SP2 peptides identified from the screen exhibited strong affinity toward SARS-CoV-2-specific &#x03B3;&#x03B4;TCRs. Interestingly, it appeared that SARS-CoV-2 ORF1ab regions harbor the sequences encoding these epitopes. Specifically, NSP8, a non-structural protein, contains the sequences matching both epitopes. Considering the limitations within our screen model, further study is needed to test the effects of NSP8 protein on COVID-19 patients&#x2019; peripheral &#x03B3;&#x03B4;T cells.</p>
<p>The polyprotein encoded by ORF1ab gene segment is composed of sixteen non-structural proteins including NSP8 (<xref ref-type="bibr" rid="B5">Biswas et al., 2021</xref>). NSP8 initiates the synthesis of complementary short oligonucleotides and provides RNA primers required by NSP12 during viral replication and transcription (<xref ref-type="bibr" rid="B13">Imbert et al., 2006</xref>). It has been suggested that NSP8, being engaged in specific cytoplasmic foci, can form complexes with NSP7, NSP9, and NSP10 (<xref ref-type="bibr" rid="B36">Zhai et al., 2005</xref>; <xref ref-type="bibr" rid="B1">Achour, 2021</xref>) and suppress protein integration into cytoplasmic membrane thereby mitigate the interferon response of host cells (<xref ref-type="bibr" rid="B4">Banerjee et al., 2020</xref>; <xref ref-type="bibr" rid="B10">Gu et al., 2022</xref>). Recent studies highlighted the possibility of NSP8 as an antigenic target of SARS-CoV-2 (<xref ref-type="bibr" rid="B2">Ahmad et al., 2020</xref>; <xref ref-type="bibr" rid="B21">Ong et al., 2020</xref>). Our results reveal that NSP8 mediates the recognition of SARS-CoV-2 by &#x03B3;&#x03B4;TCR (<xref ref-type="fig" rid="F3">Figure 3</xref>). This finding provides new opportunities for developing alternative vaccines through targeting non-structural proteins, which is also encouraged by the study of another non-structural protein, NS1, showing interesting potentials in both promoting immune protection and reducing viral replication (<xref ref-type="bibr" rid="B25">Salat et al., 2020</xref>). Moreover, antibodies induced by non-structural protein vaccines can bypass the issue with antibody-dependent enhancement (ADE).</p>
<p>SARS-CoV-2 variants can evade vaccine-induced immunity, leading to increases in transmissibility, infectivity, hospitalization, and mortality (<xref ref-type="bibr" rid="B3">Alkhatib et al., 2021</xref>; <xref ref-type="bibr" rid="B26">Singh et al., 2021</xref>). Importantly, we did not detect any hotspots of mutation related to all variants identified so far in SP1 and SP2 epitopes (data not shown). Few genomic alterations occur in the NSP8-encoding sequences (<xref ref-type="bibr" rid="B16">Koyama et al., 2020</xref>), highly likely due to the fact that no significant positive selection pressure upon these sequences as indicated by the <italic>in silico</italic> analysis<sup><xref ref-type="fn" rid="footnote3">3</xref></sup> (data not shown).</p>
</sec>
<sec id="S5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="S6">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by the protocol for our study had received approvals from the Clinical Ethics Committee of Hubei University of Medicine, Shiyan City (No. 2020-TH-017). The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="S7">
<title>Author contributions</title>
<p>XX and YW conceived and designed the experiments. BD and YG performed the experiments. XX, BD, and YW analyzed the data. YZ and GL contributed to the reagents, materials, and/or analysis tools. XX and BD wrote the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="conf1" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="pudiscl1" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<sec id="S8" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported by the Hubei Provincial Natural Science Foundation (2021CFA009), Health Commission of Hubei Province (WJ2021M057), the Scientific and Technological Project of Shiyan City of Hubei Province (2021K62), the Emergency Research Project for COVID-19 of Shiyan City (No. 20Y01), Provincial advantageous discipline group project of Hubei University of Medicine (2022XKQ01), and the Biomedical Research Foundation, Hubei University of Medicine (HBMUPI201806). The funding agents had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Achour</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Identification of oligopeptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non structural protein 8 (NSP8) and their similarities with type 1 angiotensin II receptor key sites.</article-title> <source><italic>Biomed. Pharmacother.</italic></source> <volume>141</volume>:<fpage>111722</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111722</pub-id> <pub-id pub-id-type="pmid">34144455</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname> <given-names>S.</given-names></name> <name><surname>Navid</surname> <given-names>A.</given-names></name> <name><surname>Farid</surname> <given-names>R.</given-names></name> <name><surname>Abbas</surname> <given-names>G.</given-names></name> <name><surname>Ahmad</surname> <given-names>F.</given-names></name> <name><surname>Zaman</surname> <given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics.</article-title> <source><italic>Eur. J. Pharm. Sci.</italic></source> <volume>151</volume>:<fpage>105387</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2020.105387</pub-id> <pub-id pub-id-type="pmid">32454128</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alkhatib</surname> <given-names>M.</given-names></name> <name><surname>Svicher</surname> <given-names>V.</given-names></name> <name><surname>Salpini</surname> <given-names>R.</given-names></name> <name><surname>Ambrosio</surname> <given-names>F. A.</given-names></name> <name><surname>Bellocchi</surname> <given-names>M. C.</given-names></name> <name><surname>Carioti</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021.</article-title> <source><italic>Microbiol. Spectr.</italic></source> <volume>9</volume>:<fpage>e0109621</fpage>. <pub-id pub-id-type="doi">10.1128/Spectrum.01096-21</pub-id> <pub-id pub-id-type="pmid">34787497</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname> <given-names>A. K.</given-names></name> <name><surname>Blanco</surname> <given-names>M. R.</given-names></name> <name><surname>Bruce</surname> <given-names>E. A.</given-names></name> <name><surname>Honson</surname> <given-names>D. D.</given-names></name> <name><surname>Chen</surname> <given-names>L. M.</given-names></name> <name><surname>Chow</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses.</article-title> <source><italic>Cell</italic></source> <volume>183</volume> <fpage>1325</fpage>&#x2013;<lpage>1339.e21</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.004</pub-id> <pub-id pub-id-type="pmid">33080218</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname> <given-names>N.</given-names></name> <name><surname>Kumar</surname> <given-names>K.</given-names></name> <name><surname>Mallick</surname> <given-names>P.</given-names></name> <name><surname>Das</surname> <given-names>S.</given-names></name> <name><surname>Kamal</surname> <given-names>I. M.</given-names></name> <name><surname>Bose</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Structural and Drug Screening Analysis of the Non-structural Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Virus Extracted From Indian Coronavirus Disease 2019 Patients.</article-title> <source><italic>Front. Genet.</italic></source> <volume>12</volume>:<fpage>626642</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2021.626642</pub-id> <pub-id pub-id-type="pmid">33767730</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boom</surname> <given-names>W. H.</given-names></name> <name><surname>Balaji</surname> <given-names>K. N.</given-names></name> <name><surname>Nayak</surname> <given-names>R.</given-names></name> <name><surname>Tsukaguchi</surname> <given-names>K.</given-names></name> <name><surname>Chervenak</surname> <given-names>K. A.</given-names></name></person-group> (<year>1994</year>). <article-title>Characterization of a 10- to 14-kilodalton protease-sensitive Mycobacterium tuberculosis H37Ra antigen that stimulates human gamma delta T cells.</article-title> <source><italic>Infect. Immun.</italic></source> <volume>62</volume> <fpage>5511</fpage>&#x2013;<lpage>5518</lpage>. <pub-id pub-id-type="doi">10.1128/iai.62.12.5511-5518.1994</pub-id> <pub-id pub-id-type="pmid">7960133</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>W.</given-names></name> <name><surname>He</surname> <given-names>W.</given-names></name></person-group> (<year>2005</year>). <article-title>The recognition pattern of gammadelta T cells.</article-title> <source><italic>Front. Biosci.</italic></source> <volume>10</volume> <fpage>2676</fpage>&#x2013;<lpage>2700</lpage>. <pub-id pub-id-type="doi">10.2741/1729</pub-id> <pub-id pub-id-type="pmid">15970527</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carissimo</surname> <given-names>G.</given-names></name> <name><surname>Xu</surname> <given-names>W.</given-names></name> <name><surname>Kwok</surname> <given-names>I.</given-names></name> <name><surname>Abdad</surname> <given-names>M. Y.</given-names></name> <name><surname>Chan</surname> <given-names>Y. H.</given-names></name> <name><surname>Fong</surname> <given-names>S. W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19.</article-title> <source><italic>Nat. Commun.</italic></source> <volume>11</volume>:<fpage>5243</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-19080-6</pub-id> <pub-id pub-id-type="pmid">33067472</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghadially</surname> <given-names>H.</given-names></name> <name><surname>Brown</surname> <given-names>L.</given-names></name> <name><surname>Lloyd</surname> <given-names>C.</given-names></name> <name><surname>Lewis</surname> <given-names>L.</given-names></name> <name><surname>Lewis</surname> <given-names>A.</given-names></name> <name><surname>Dillon</surname> <given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.</article-title> <source><italic>Br. J. Cancer</italic></source> <volume>116</volume> <fpage>1208</fpage>&#x2013;<lpage>1217</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2017.79</pub-id> <pub-id pub-id-type="pmid">28334733</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>W.</given-names></name> <name><surname>Gan</surname> <given-names>H.</given-names></name> <name><surname>Ma</surname> <given-names>Y.</given-names></name> <name><surname>Xu</surname> <given-names>L.</given-names></name> <name><surname>Cheng</surname> <given-names>Z. J.</given-names></name> <name><surname>Li</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity.</article-title> <source><italic>Virol. J.</italic></source> <volume>19</volume>:<fpage>49</fpage>.</citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirsh</surname> <given-names>M. I.</given-names></name> <name><surname>Junger</surname> <given-names>W. G.</given-names></name></person-group> (<year>2008</year>). <article-title>Roles of heat shock proteins and gamma delta T cells in inflammation.</article-title> <source><italic>Am. J. Respir. Cell Mol. Biol.</italic></source> <volume>39</volume> <fpage>509</fpage>&#x2013;<lpage>513</lpage>.</citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holtmeier</surname> <given-names>W.</given-names></name> <name><surname>Kabelitz</surname> <given-names>D.</given-names></name></person-group> (<year>2005</year>). <article-title>gammadelta T cells link innate and adaptive immune responses.</article-title> <source><italic>Chem. Immunol. Allergy</italic></source> <volume>86</volume> <fpage>151</fpage>&#x2013;<lpage>183</lpage>.</citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imbert</surname> <given-names>I.</given-names></name> <name><surname>Guillemot</surname> <given-names>J. C.</given-names></name> <name><surname>Bourhis</surname> <given-names>J. M.</given-names></name> <name><surname>Bussetta</surname> <given-names>C.</given-names></name> <name><surname>Coutard</surname> <given-names>B.</given-names></name> <name><surname>Egloff</surname> <given-names>M. P.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus.</article-title> <source><italic>EMBO J.</italic></source> <volume>25</volume> <fpage>4933</fpage>&#x2013;<lpage>4942</lpage>. <pub-id pub-id-type="doi">10.1038/sj.emboj.7601368</pub-id> <pub-id pub-id-type="pmid">17024178</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>Y.</given-names></name> <name><surname>Yang</surname> <given-names>H.</given-names></name> <name><surname>Ji</surname> <given-names>W.</given-names></name> <name><surname>Wu</surname> <given-names>W.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Zhang</surname> <given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Virology, Epidemiology, Pathogenesis, and Control of COVID-19.</article-title> <source><italic>Viruses</italic></source> <volume>12</volume>:<fpage>372</fpage>.</citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jouan</surname> <given-names>Y.</given-names></name> <name><surname>Guillon</surname> <given-names>A.</given-names></name> <name><surname>Gonzalez</surname> <given-names>L.</given-names></name> <name><surname>Perez</surname> <given-names>Y.</given-names></name> <name><surname>Boisseau</surname> <given-names>C.</given-names></name> <name><surname>Ehrmann</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients.</article-title> <source><italic>J. Exp. Med.</italic></source> <volume>217</volume>:<fpage>e20200872</fpage>. <pub-id pub-id-type="doi">10.1084/jem.20200872</pub-id> <pub-id pub-id-type="pmid">32886755</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname> <given-names>T.</given-names></name> <name><surname>Platt</surname> <given-names>D.</given-names></name> <name><surname>Parida</surname> <given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Variant analysis of SARS-CoV-2 genomes.</article-title> <source><italic>Bull. World Health Organ.</italic></source> <volume>98</volume> <fpage>495</fpage>&#x2013;<lpage>504</lpage>.</citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname> <given-names>L.</given-names></name> <name><surname>Qian</surname> <given-names>H.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>D.</given-names></name> <name><surname>Dai</surname> <given-names>T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The phenotypic changes of gammadelta T cells in COVID-19 patients.</article-title> <source><italic>J. Cell. Mol. Med.</italic></source> <volume>24</volume> <fpage>11603</fpage>&#x2013;<lpage>11606</lpage>.</citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo Presti</surname> <given-names>E.</given-names></name> <name><surname>Dieli</surname> <given-names>F.</given-names></name> <name><surname>Meraviglia</surname> <given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Lymphopenia in COVID-19: gammadelta T Cells-Based Therapeutic Opportunities.</article-title> <source><italic>Vaccines</italic></source> <volume>9</volume>:<fpage>562</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9060562</pub-id> <pub-id pub-id-type="pmid">34071430</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morath</surname> <given-names>A.</given-names></name> <name><surname>Schamel</surname> <given-names>W. W.</given-names></name></person-group> (<year>2020</year>). <article-title>alphabeta and gammadelta T cell receptors: similar but different.</article-title> <source><italic>J. Leukoc. Biol.</italic></source> <volume>107</volume> <fpage>1045</fpage>&#x2013;<lpage>1055</lpage>.</citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Odak</surname> <given-names>I.</given-names></name> <name><surname>Barros-Martins</surname> <given-names>J.</given-names></name> <name><surname>Bosnjak</surname> <given-names>B.</given-names></name> <name><surname>Stahl</surname> <given-names>K.</given-names></name> <name><surname>David</surname> <given-names>S.</given-names></name> <name><surname>Wiesner</surname> <given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Reappearance of effector T cells is associated with recovery from COVID-19.</article-title> <source><italic>EBioMedicine</italic></source> <volume>57</volume>:<fpage>102885</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102885</pub-id> <pub-id pub-id-type="pmid">32650275</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname> <given-names>E.</given-names></name> <name><surname>Wong</surname> <given-names>M. U.</given-names></name> <name><surname>Huffman</surname> <given-names>A.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.</article-title> <source><italic>Front. Immunol.</italic></source> <volume>11</volume>:<fpage>1581</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01581</pub-id> <pub-id pub-id-type="pmid">32719684</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orumaa</surname> <given-names>K.</given-names></name> <name><surname>Dunne</surname> <given-names>M. R.</given-names></name></person-group> (<year>2022</year>). <article-title>The role of unconventional T cells in COVID-19.</article-title> <source><italic>Ir. J. Med. Sci.</italic></source> <volume>191</volume> <fpage>519</fpage>&#x2013;<lpage>528</lpage>.</citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rijkers</surname> <given-names>G.</given-names></name> <name><surname>Vervenne</surname> <given-names>T.</given-names></name> <name><surname>van der Pol</surname> <given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>More bricks in the wall against SARS-CoV-2 infection: involvement of gamma9delta2 T cells.</article-title> <source><italic>Cell. Mol. Immunol.</italic></source> <volume>17</volume> <fpage>771</fpage>&#x2013;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0473-0</pub-id> <pub-id pub-id-type="pmid">32467616</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname> <given-names>R. E.</given-names></name> <name><surname>Torres</surname> <given-names>M.</given-names></name> <name><surname>Fournie</surname> <given-names>J. J.</given-names></name> <name><surname>Harding</surname> <given-names>C. V.</given-names></name> <name><surname>Boom</surname> <given-names>W. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Phosphoantigen presentation by macrophages to mycobacterium tuberculosis&#x2013;reactive Vgamma9Vdelta2+ T cells: modulation by chloroquine.</article-title> <source><italic>Infect. Immun.</italic></source> <volume>70</volume> <fpage>4019</fpage>&#x2013;<lpage>4027</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.8.4019-4027.2002</pub-id> <pub-id pub-id-type="pmid">12117907</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salat</surname> <given-names>J.</given-names></name> <name><surname>Mikulasek</surname> <given-names>K.</given-names></name> <name><surname>Larralde</surname> <given-names>O.</given-names></name> <name><surname>Pokorna Formanova</surname> <given-names>P.</given-names></name> <name><surname>Chrdle</surname> <given-names>A.</given-names></name> <name><surname>Haviernik</surname> <given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and may Elicit NS1-Specific Antibody Responses in Vaccinated Individuals.</article-title> <source><italic>Vaccines</italic></source> <volume>8</volume>:<fpage>81</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines8010081</pub-id> <pub-id pub-id-type="pmid">32059489</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>D. D.</given-names></name> <name><surname>Parveen</surname> <given-names>A.</given-names></name> <name><surname>Yadav</surname> <given-names>D. K.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines.</article-title> <source><italic>Front. Cell. Infect. Microbiol.</italic></source> <volume>11</volume>:<fpage>777212</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2021.777212</pub-id> <pub-id pub-id-type="pmid">34970509</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname> <given-names>C. T.</given-names></name> <name><surname>Abate</surname> <given-names>G.</given-names></name> <name><surname>Blazevic</surname> <given-names>A.</given-names></name> <name><surname>Hoft</surname> <given-names>D. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity.</article-title> <source><italic>J. Immunol.</italic></source> <volume>181</volume> <fpage>4471</fpage>&#x2013;<lpage>4484</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.7.4471</pub-id> <pub-id pub-id-type="pmid">18802050</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname> <given-names>X.</given-names></name> <name><surname>Cui</surname> <given-names>L.</given-names></name> <name><surname>He</surname> <given-names>W.</given-names></name></person-group> (<year>2010</year>). <article-title>The recognition of gammadelta TCR to protein antigen does not depend on the hydrophobic I97 residue of CDR3delta.</article-title> <source><italic>Int. Immunol.</italic></source> <volume>22</volume> <fpage>299</fpage>&#x2013;<lpage>306</lpage>.</citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname> <given-names>X.</given-names></name> <name><surname>Guo</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>H.</given-names></name> <name><surname>Xu</surname> <given-names>C.</given-names></name> <name><surname>Zhang</surname> <given-names>H.</given-names></name> <name><surname>Hu</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Antigen specificity of gammadelta T cells depends primarily on the flanking sequences of CDR3delta.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>284</volume> <fpage>27449</fpage>&#x2013;<lpage>27455</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.011684</pub-id> <pub-id pub-id-type="pmid">19666468</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname> <given-names>X.</given-names></name> <name><surname>Guo</surname> <given-names>Y.</given-names></name> <name><surname>Zhu</surname> <given-names>M.</given-names></name> <name><surname>Qiu</surname> <given-names>F.</given-names></name> <name><surname>Lei</surname> <given-names>F.</given-names></name> <name><surname>Li</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Identification of new potential antigen recognized by gammadeltaT cells in hepatocellular carcinoma.</article-title> <source><italic>Cancer Immunol. Immunother.</italic></source> <volume>70</volume> <fpage>1917</fpage>&#x2013;<lpage>1927</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-020-02826-y</pub-id> <pub-id pub-id-type="pmid">33399933</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname> <given-names>X.</given-names></name> <name><surname>Han</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>L.</given-names></name> <name><surname>Zhao</surname> <given-names>Z.</given-names></name></person-group> (<year>2011a</year>). <article-title>Gammadelta T cells response to Mycobacterium tuberculosis in pulmonary tuberculosis patients using preponderant complementary determinant region 3 sequence.</article-title> <source><italic>Indian J. Med. Res.</italic></source> <volume>134</volume> <fpage>356</fpage>&#x2013;<lpage>361</lpage>.</citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>B.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Huang</surname> <given-names>H.</given-names></name> <name><surname>Cui</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2011b</year>). <article-title>A novel strategy to screen Bacillus Calmette-Guerin protein antigen recognized by gammadelta TCR.</article-title> <source><italic>PLoS One</italic></source> <volume>6</volume>:<fpage>e18809</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0018809</pub-id> <pub-id pub-id-type="pmid">21526117</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname> <given-names>X.</given-names></name> <name><surname>Han</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>L.</given-names></name> <name><surname>Zhao</surname> <given-names>Z.</given-names></name></person-group> (<year>2013</year>). <article-title>Identification of a new tuberculosis antigen recognized by gammadelta T cell receptor.</article-title> <source><italic>Clin. Vaccine Immunol.</italic></source> <volume>20</volume> <fpage>530</fpage>&#x2013;<lpage>539</lpage>.</citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Y.</given-names></name> <name><surname>Xiao</surname> <given-names>Z.</given-names></name> <name><surname>Ye</surname> <given-names>K.</given-names></name> <name><surname>He</surname> <given-names>X.</given-names></name> <name><surname>Sun</surname> <given-names>B.</given-names></name> <name><surname>Qin</surname> <given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2: characteristics and current advances in research.</article-title> <source><italic>Virol. J.</italic></source> <volume>17</volume>:<fpage>117</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-020-01369-z</pub-id> <pub-id pub-id-type="pmid">32727485</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yazdanifar</surname> <given-names>M.</given-names></name> <name><surname>Mashkour</surname> <given-names>N.</given-names></name> <name><surname>Bertaina</surname> <given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Making a case for using gammadelta T cells against SARS-CoV-2.</article-title> <source><italic>Crit. Rev. Microbiol.</italic></source> <volume>46</volume> <fpage>689</fpage>&#x2013;<lpage>702</lpage>.</citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname> <given-names>Y.</given-names></name> <name><surname>Sun</surname> <given-names>F.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Pang</surname> <given-names>H.</given-names></name> <name><surname>Xu</surname> <given-names>X.</given-names></name> <name><surname>Bartlam</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer.</article-title> <source><italic>Nat. Struct. Mol. Biol.</italic></source> <volume>12</volume> <fpage>980</fpage>&#x2013;<lpage>986</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb999</pub-id> <pub-id pub-id-type="pmid">16228002</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>R.</given-names></name> <name><surname>Zheng</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>B.</given-names></name> <name><surname>Wei</surname> <given-names>H.</given-names></name> <name><surname>Tian</surname> <given-names>Z.</given-names></name></person-group> (<year>2006</year>). <article-title>Human NK cells positively regulate gammadelta T cells in response to Mycobacterium tuberculosis.</article-title> <source><italic>J. Immunol.</italic></source> <volume>176</volume> <fpage>2610</fpage>&#x2013;<lpage>2616</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.176.4.2610</pub-id> <pub-id pub-id-type="pmid">16456023</pub-id></citation></ref>
</ref-list>
<fn-group>
<fn id="footnote1">
<label>1</label>
<p><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link></p></fn>
<fn id="footnote2">
<label>2</label>
<p><ext-link ext-link-type="uri" xlink:href="http://heliquest.ipmc.cnrs.fr">http://heliquest.ipmc.cnrs.fr</ext-link></p></fn>
<fn id="footnote3">
<label>3</label>
<p><ext-link ext-link-type="uri" xlink:href="http://www.datamonkey.org/meme">http://www.datamonkey.org/meme</ext-link></p></fn>
</fn-group>
</back>
</article>